Stakeholder involvement has been proposed as a key strategy for appropriately managing value-laden decisions or 'value judgments' in health economics modelling. Philosophers of science, however, conceive of stakeholder involvement in research in conflicting ways, and also propose alternative strategies for 'managing values' in science. Furthermore, all proposed strategies for managing values in science raise philosophical questions and practical challenges that are difficult to resolve. As a result, health economists who seek to appropriately inform value judgments in modelling must currently go without straightforward guidance. There is a need to further explore how health economists should manage value judgments in modelling, taking into account philosophical debates and contextual constraints. This paper discusses core proposals for managing values in science and identifies philosophical questions and practical challenges these proposals leave unresolved. It further considers how this could potentially inform processes to manage value judgments in health economics modelling, using examples from an ongoing modelling project called LEAP (Lifetime Exposures and Asthma Outcomes Projection). We conclude that all strategies to 'manage values' in health economics modelling have strengths and weaknesses, but are generally compatible with one another, suggesting that health economists may use a combination of strategies. Further research is needed to explore the effects of strategies to 'manage values' in health economics modelling.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.socscimed.2024.117256 | DOI Listing |
Mod Rheumatol
January 2025
Department of Rheumatology, Kameda Medical Center.
Objectives: To investigate the factors affecting laboratory data and computed tomography (CT) attenuation values of L1 trabecular and femoral bone marrow, potential markers for differentiating between adult-onset Still's disease and intravascular large B-cell lymphoma.
Methods: We conducted a retrospective observational study on patients diagnosed with adult-onset Still's disease or intravascular large B-cell lymphoma. Clinical and laboratory data, and CT attenuation values of the bone marrow were compared.
J Manag Care Spec Pharm
January 2025
Academy of Managed Care Pharmacy Foundation, Alexandria, VA.
Background: Over the past 5 years, managed care pharmacy has been shaped by a global pandemic, advancements in generative artificial intelligence (AI), Medicare drug price negotiation policies, and significant therapeutic developments. Collective intelligence methods can be used to anticipate future developments in practice to help organizations plan and develop new strategies around those changes.
Objective: To identify emerging trends in managed care pharmacy.
J Plast Surg Hand Surg
January 2025
Department of Plastic and Reconstructive Surgery, Skåne University Hospital, Malmö, Sweden.
Introduction: Health-related quality of life (HR-QoL) outcomes following maxillary reconstruction with the scapular osseous free flap (SOFF) are lacking. Material and Methods: To determine these outcomes, a study of patients who completed maxillary reconstruction with flap survival of the SOFF between 2016 and 2023 was conducted, using Face-Q Head and Neck Cancer Module (FACE-Q).
Results: Eligible patients had at least six months of follow-up.
J Environ Sci Health B
January 2025
Faculty of Food Technology, University of Economics-Technology for Industries (UNETI), Hanoi, Vietnam.
Antibiotic residues have become serious health concerns due to the development of antibiotic-resistant bacteria. The treatment of antibiotic pollutants in wastewater is necessary for reducing the issue of antibiotic resistance. In this work, the metal oxide photocatalyst titanium dioxide (TiO) was evaluated for the removal of the tetracycline antibiotic (TC-A) and the deactivation of bacteria (E-B) from wastewater.
View Article and Find Full Text PDFBJU Int
January 2025
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objective: To evaluate the association between tumour size and the growth rate (GR) of small renal masses (SRMs) in patients managed by active surveillance (AS).
Materials And Methods: We queried the prospective, multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry for patients on AS with an imaging interval of ≥6 months, identifying 456 patients. We tracked tumour size over time; a GR >0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!